Plain-English translation of NCT07177911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called for people with moderate-to-severe lupus (a disease where the immune system attacks the body's own tissues). Researchers want to understand how safe the medication is, how well it works, and how the body processes it. Half of participants will receive and half will receive a placebo (a look-alike with no active ingredient).
Many people with lupus don't get enough relief from existing treatments and continue to experience serious symptoms. This medication is being tested as a potential new option for patients whose lupus isn't controlled well enough with current therapies.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic multiple times over several weeks to receive doses of either the medication or placebo. At each visit, researchers would check your health with blood tests, physical exams, and questionnaires about your lupus symptoms. The study is designed to start with low doses and gradually increase them while carefully monitoring your safety and how well the treatment works. Your participation would involve close follow-up even after the treatment phase ends.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
CytoCares Inc
Enrollment target
~32 participants
Started
September 2025
Primary completion
September 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
CEO
CytoCares Inc
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.